Gentris has named Gary Pace vice president for corporate development, the company said Jan. 16. Pace, 49, comes to the pharmacogenomics company from stints at Allied-Signal, United AgiSeeds, Ciba-Geigey, and Novartis, where he was a patent attorney.
The company also promoted two staffers: David Gessner, 50, has been named vice president of business development, and Scott Clark, 36, was appointed executive director of laboratory services, Gentris said.
Epigenomics has named to its scientific advisory board: Johns Hopkins University professor Andrew Feinberg and Sydney Cancer Center associate professor Susan Clark.
Feinberg’s lab discovered CpG islands that are methylated in normal cells but are unmethylated in the diseased state. These will be used in Epigenomics’ marker-development pipeline.
Clark developed bisulfite sequencing, which helps detect methylation at any given cytosine in DNA. Subsequently, she discovered potentially useful diagnostic markers for the early detection of prostate cancer.